Momenta Pharmaceuticals, Inc. (MNTA)

[tinkershaw]

Strongly suggest that this is very much missing the point of the enox demonstrated Momenta patent strategy

No, did not miss the point. My point was that Mylan CANNOT prove sameness to the point that enoxaparin approval required so it will be irrelevant. Mylan's drug is not characteristically "identical" which is more precisely what the FDA is looking for, however that term of art is defined.

I agree with you, however, if Mylan thinks they can rejigger the formulation (if that is even possible - and Teva seems to be having difficulty here to say the least in enoxaparin) then the patents would come into play.

But I think arguing semantics here, the result either way is the same...which is to say, GOOD for MNTA.

Tinker